Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) SEC filings page provides access to the company’s official U.S. Securities and Exchange Commission disclosures, with AI-powered tools to help interpret complex documents. As a clinical-stage biotechnology company focused on NK cell therapies for autoimmune diseases and cancers, Artiva uses filings such as Forms 8-K, 10-Q and 10-K to report material events, financial results and risk factors.
Recent Form 8-K filings highlighted in the available data include current reports on quarterly financial results, initial safety and translational data for AlloNK (AB-101) in autoimmune disease, and corporate matters such as amendments to the 2024 Equity Incentive Plan and equity award exchanges for certain executives. Other 8-Ks reference FDA Fast Track Designation for AlloNK in refractory rheumatoid arthritis and summarize clinical findings from ongoing Phase 1 and 2 trials combining AlloNK with anti-CD20 monoclonal antibodies after cyclophosphamide and fludarabine conditioning.
Through this page, users can review Artiva’s periodic reports, including 10-Q and 10-K filings, to understand research and development expenses, cash, cash equivalents and investments, net losses, and other financial information the company reports. AI-generated summaries can highlight key sections related to AlloNK’s clinical development, the CAR-NK oncology pipeline, the strategic partnership with GC Cell for NK cell manufacturing technology, and the company’s stated risk factors.
Investors can also reference proxy materials and equity plan amendments to see how Artiva structures compensation and equity incentives, as illustrated by the amendment to the 2024 Equity Incentive Plan approved at the 2025 Annual Meeting. Form 4 insider transaction reports, when available, can be used to monitor equity activity by directors and officers. Real-time updates from EDGAR combined with AI explanations help make ARTV’s regulatory record more accessible to readers who want to understand the company’s clinical, financial and governance disclosures in detail.
Huston Thad Allen reported acquisition or exercise transactions in this Form 4 filing.
Artiva Biotherapeutics’ Chief Financial Officer, Thad Allen Huston, received an equity award of 220,000 shares of common stock on March 10, 2026. The Form 4 describes this as a restricted stock unit grant under the company’s 2025 Inducement Plan, with no cash purchase price and resulting direct ownership of 220,000 shares.
Artiva Biotherapeutics’ 2025 annual report shows a deeper investment phase as it advances its lead NK cell therapy, AlloNK, for autoimmune diseases and cancer. The company reported a net loss of $83.9 million for 2025, up from $65.4 million in 2024, driven mainly by higher R&D spending.
Research and development expenses rose to $69.5 million, with $32.4 million tied to AlloNK and $26.3 million in personnel costs, reflecting expanded clinical and manufacturing activity. General and administrative expenses increased to $20.3 million, primarily from higher headcount and legal and operational costs.
Artiva ended 2025 with $108.0 million in cash, cash equivalents and investments and an accumulated deficit of $330.5 million. Management believes this cash position will fund operations into the second quarter of 2027. An at-the-market equity program for up to $11.95 million remains unused, providing additional potential financing flexibility. The company continues to prioritize refractory rheumatoid arthritis for AlloNK and plans initial response data from more than 15 refractory RA patients and FDA discussions on pivotal trial design in the first half of 2026.
Artiva Biotherapeutics reported a larger 2025 net loss as it advanced its AlloNK cell therapy program toward potential registrational development in refractory rheumatoid arthritis. Net loss was $83.9 million for 2025, compared with $65.4 million in 2024, driven mainly by higher research and development spending of $69.5 million and general and administrative expenses of $20.3 million.
The company ended 2025 with cash, cash equivalents and investments of $108.0 million, which it expects will fund operations into Q2 2027. AlloNK received FDA Fast Track designation in refractory RA, showed deep B-cell depletion and a favorable outpatient safety profile across multiple autoimmune diseases, and earlier oncology data in lymphoma demonstrated a 64% complete response rate with durable outcomes. Initial clinical response data in refractory RA and an FDA interaction on potential pivotal trial design are both anticipated in the first half of 2026.
Artiva Biotherapeutics, Inc. executive Huston Thad Allen, the company’s Chief Financial Officer, filed an initial ownership report on Form 3 for ARTV. The filing lists him as an officer and does not report any share transactions, serving as a baseline disclosure of his status as an insider.
Artiva Biotherapeutics appointed Thad Huston as Chief Financial Officer, effective February 18, 2026, making him the company’s principal financial and accounting officer. He brings more than 30 years of global finance and operational experience across large pharmaceutical, biotech and medical device companies.
Under his employment agreement, Huston will receive a base salary of $540,000 and will be eligible for an annual cash bonus targeted at 40% of base salary, with his 2026 bonus calculated as if he started on January 1, 2026. As an inducement to join, he will be granted 220,000 restricted stock units under the 2025 Inducement Plan, vesting over four years starting February 15, 2027, subject to continued employment and the filing of a Form S-8.
If terminated without cause or he resigns for good reason, Huston may receive salary continuation, COBRA benefits and partial equity vesting, with enhanced cash and full time-based equity acceleration if such a termination occurs in connection with a change of control, contingent on signing a release of claims.
Sorg Elaine K. reported acquisition or exercise transactions in this Form 4 filing.
Artiva Biotherapeutics director receives stock option grant
Artiva Biotherapeutics, Inc. director Elaine K. Sorg was granted a Director Stock Option covering 27,500 shares on February 18, 2026. The option has a grant price of $0.00 per share, reflecting a compensatory award rather than an open-market purchase.
According to the vesting terms, one-third of the 27,500 shares vested following the grant date. The remaining shares vest monthly over an additional two years following February 18, 2026, aligning the director’s compensation with longer-term company performance.
Artiva Biotherapeutics, Inc. filed an initial insider ownership report for director Elaine K. Sorg on Form 3. The filing lists her status as a director and does not report any insider transactions or share purchases or sales at this time.
Artiva Biotherapeutics, Inc. appointed Elaine Sorg as a Class I director, with her term running until the company’s 2028 annual meeting of stockholders. The Board acted on the recommendation of its Nominating and Corporate Governance Committee, and there are no related-party arrangements or transactions requiring disclosure.
Ms. Sorg brings more than 35 years of senior executive experience at major pharmaceutical companies, including roles as Senior Vice President and President of AbbVie’s U.S. commercial operations until her retirement in January 2024. She also serves on the board of CSL Limited, on Purdue University’s Dean’s Advisory Council, as a Senior Advisor at Boston Consulting Group, and on the Scientific Strategy Board of Galapagos.
Under Artiva’s Non-Employee Director Compensation Policy, she will receive an annual cash retainer of $40,000 and an initial option to purchase 27,500 shares of common stock, with one-third vesting shortly after grant and the remainder vesting monthly over two additional years, subject to continuous service. She is also eligible for automatic annual option grants to purchase 13,750 shares at each annual meeting, vesting over about one year, with all such options vesting in full upon a change in control, subject to the plan terms.
Artiva Biotherapeutics reported that SVP of Research and Development Heather Raymon received a grant of 46,000 shares of common stock in the form of restricted stock units under the company’s 2024 Equity Incentive Plan. On the same date, 1,521 shares at $4.00 per share were withheld to cover income tax obligations linked to restricted stock unit vesting, leaving Raymon with 151,323 directly owned shares.
Artiva Biotherapeutics, Inc. Chief Tech Operations Officer Christopher Horan reported equity compensation and a related tax withholding transaction in company stock. He received a grant of 117,300 shares of common stock as a restricted stock unit award under the company’s 2024 Equity Incentive Plan. On the same date, 2,187 shares of common stock at a price of $4.00 per share were withheld by the company to cover income tax obligations arising from the vesting of restricted stock unit awards. After these transactions, Horan directly owned 300,452 shares of Artiva’s common stock.